Clinical Trial Update: START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating a Sensipar (cinacalcet) treatment algorithm to reach K/DOQI targets in chronic kidney disease patients with secondary hyperparathyroidi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• SENSIPAR (CINACALCET HYDROCHLORIDE)

Snippet

Sponsor: Amgen | Conditions: Kidney Disease, Secondary Hyperparathyroidism | Phase 4 | Status: COMPLETED